Project Grant HT94252310982
Award Date 9/15/23
Completion Date 9/14/27
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $920,228 project grant to the University of Colorado-Denver on September 15, 2023. The grant, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", will fund research to investigate the role of androgen receptors in luminal breast cancer and their impact on response to endocrine...
- The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,260,839 Project Grant to the University of Colorado-Denver. The grant, titled "Targeting EHMT1/2 to Overcome Therapy-Resistant Ovarian Cancer," will fund advanced biomedical research aimed at developing novel diagnostic tools and therapeutic interventions for ovarian cancer. The research project, spanning from May 2025 to April 2029, will investigate the role of the...
- The federal Project Grant award of $2,271,024.00 was provided by the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) federal grant program, to the University of Colorado-Denver. The award, effective November 1, 2024, supports a four-year research project to improve understanding of next-generation immunotherapy responses in metastatic uveal melanoma. The University of Colorado-Denver, a major public research university with a strong focus on medical...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of Colorado-Denver a Project Grant totaling $904,982 under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2026, through May 31, 2029. The research project focuses on the use of unconventional immune cells to treat rare melanomas and understand immunotherapy resistance. This three-year initiative aligns with the DHA's broader mission to transform health care for...
- Federal Grant Award Summary The University of Colorado-Denver received a $842,067 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award funds investigator-initiated research to overcome resistance to BRAF-directed therapy in advanced thyroid cancer, a condition relevant to Service Member health and the military population. The three-year project will be...
- The University of Colorado-Denver has been awarded a $1,130,984 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "DEFINING AND TARGETING CHROMOBOX2 (CBX2)-MEDIATED CHEMORESISTANCE IN HIGH GRADE SEROUS CARCINOMA". The grant will support the university's research efforts to investigate novel approaches for overcoming chemoresistance in high-grade serous carcinoma, a form of ovarian cancer, over a...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, a $1.18M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2029. The award supports investigator-initiated research on the use of unconventional immune cells to treat rare melanomas and understand immunotherapy resistance. The three-year project will...
- Federal Project Grant Award Summary The Defense Health Agency awarded $1.4 million to The Regents of the University of Colorado (University of Colorado-Denver) under the Military Medical Research and Development program (CFDA 12.420) for a three-year project beginning July 1, 2026 and concluding June 30, 2029. The funded research focuses on enhancing Linker for Activation of T cells (LAT) activity in Chimeric Antigen Receptor (CAR) T cell therapies for Ewing sarcoma, a pediatric malignancy. This...
- The University of Colorado was awarded a $577,680.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research to target EHMT1/2 to overcome therapy-resistant ovarian cancer. The project aims to transform healthcare for military service members, veterans, and the broader public by developing novel diagnostic tools, therapeutic interventions, and clinical practice guidelines to address critical health...
- The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...